- Johnson & Johnson shares fell sharply on October 13 after a steep decline in reported profit overshadowed higher sales and raised earnings guidance, with a proposed talc litigation resolution and weaker-than-expected medical technology sales weighing on investor sentiment.
Johnson & Johnson (NYSE: JNJ) stock dropped roughly 6% on October 13 after the healthcare company reported third-quarter results that included a large one-time charge tied to its proposed talc litigation resolution, the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines.
The shares fell even though the company beat analysts’ adjusted earnings estimates and slightly exceeded revenue expectations. Investors also reacted to slower growth in its MedTech division, which missed Wall Street forecasts for a second consecutive quarter.
In its October 13 earnings release, Johnson & Johnson reported third-quarter sales of $25.4 billion, up 5.9% from a year earlier. Reported net earnings, however, plunged 95.9% to $210 million, or $0.09 per diluted share, from $5.15 billion, or $2.12 per share, in the prior-year period.
Adjusted earnings came in at $2.59 per share, down 7.5% year over year but above the consensus estimate of $2.53 cited by market reports.
The gap between reported and adjusted earnings was central to the market reaction. The company’s reported results included special items associated with its proposed litigation resolution and strategic transactions, while adjusted figures excluded specified costs.
The selloff also reflected concerns about the company’s medical technology business. MedTech sales rose 2.5% to $8.64 billion, below analyst expectations of approximately $8.71 billion. By comparison, Innovative Medicine sales increased 7.7% to $16.76 billion.
The decline placed Johnson & Johnson among the biggest drags on the Dow Jones Industrial Average that day. The broader healthcare sector has also faced uneven performance, even as some drugmakers and medical technology companies have delivered stronger results. Investors tracking the sector can compare J&J’s performance with other healthcare stocks that have outperformed in 2026.
How the Talc Litigation Charge Affected Johnson & Johnson Earnings
The proposed settlement of ovarian cancer lawsuits linked to talc-based products is a major part of Johnson & Johnson’s ongoing legal exposure. The company announced in July that it had reached an agreement with leading plaintiff firms to resolve the remaining ovarian talc litigation, subject to conditions including participation by at least 95% of the remaining claims.
The proposed resolution includes a commitment of approximately $5.5 billion, with the first payment of no more than $3 billion scheduled for 2027 and no additional payments due before 2028 under the announced terms. The agreement is intended to resolve roughly 76,000 remaining ovarian talc claims, although its effectiveness depends on meeting the specified participation conditions.
The company’s announcement of the proposed talc litigation resolution said the agreement followed legal developments in the federal multidistrict litigation. Johnson & Johnson continues to deny that its talc products caused cancer and has said scientific evidence supports their safety.
The third-quarter earnings release attributed the reported earnings impact to a one-time special charge covering the proposed talc litigation resolution, Firefly Bio and the Sail Biomedicines collaboration. The company did not present the entire earnings decline as a recurring operating cost.
That distinction matters for investors. A large one-time charge can sharply reduce reported earnings without having the same effect on adjusted earnings or the company’s ongoing operating performance. However, a proposed settlement still represents a substantial financial commitment, and the final outcome remains subject to its conditions.
The litigation has weighed on the company for years, with previous settlement attempts and court proceedings creating uncertainty around the eventual financial cost. The latest proposal is designed to address a large portion of the remaining claims, but it does not mean all possible talc-related legal exposure has disappeared.
MedTech Weakness and 2026 Guidance Also Matter for JNJ Stock
Litigation was not the only factor behind the stock decline. Johnson & Johnson’s MedTech business delivered slower growth than analysts expected, highlighting challenges across some of its medical device markets.
The company cited geopolitical tensions, European austerity measures and pricing pressure in China as factors affecting medical technology performance. Sales outside the US were broadly flat, while the business’s overall growth lagged the pharmaceutical division.
Chief Financial Officer Joe Wolk acknowledged the need to improve MedTech performance, particularly in cardiovascular and surgery. The division has now missed Wall Street expectations for two consecutive quarters, raising questions about how quickly its growth can recover.
Johnson & Johnson nevertheless raised its full-year 2026 outlook. The company expects reported sales of approximately $101.2 billion at the midpoint, representing 7.4% growth, and increased its adjusted earnings-per-share guidance by $0.06 to $11.10 at the midpoint.
The pharmaceutical business provided a stronger counterweight. Sales of the autoimmune treatment Tremfya rose 68%, helping offset declines associated with older products. The company also highlighted progress in its drug pipeline and medical technology portfolio.
Investors must weigh that operating progress against legal costs and uneven growth across business segments. A higher full-year forecast indicates management expects continued business strength, but it does not guarantee that the share price will recover immediately.
The stock’s next moves will likely depend on evidence that MedTech growth is improving, pharmaceutical sales remain resilient and the proposed litigation resolution progresses as planned. The company has also outlined plans to spin off its orthopedics business, DePuy Synthes, by mid-2027, a move that could further reshape its portfolio.
For now, the October 13 decline reflects a combination of sharply lower reported earnings, a significant one-time charge and weaker medical technology sales. Johnson & Johnson beat adjusted earnings expectations and raised guidance, but investors focused on the costs and business-line challenges that clouded an otherwise growing revenue base.